Oral anticancer medications (OAMs) are a growing and important tool in the fight against cancer. More than 120 FDA-approved OAMs were used in clinical practice in 2022, and OAMs represent more than one-third of cancer medications in the development pipeline.
PQA members and health quality professionals gathered in Baltimore, Md., May 14-16, for the 2024 PQA Annual Meeting.
The 2024 PQA Annual Meeting poster session featured 23 quality improvement and research projects. Sponsored by Pharmacy Quality Solutions, the session provided an opportunity for authors to showcase their work and for attendees to engage in insightful dialogue about healthcare quality.
PQA will host an all-member webinar on Thursday, May 30, from 1:00-1:30 p.m. ET, to discuss one health plan performance measure that is being considered for retirement: Use of Opioids from Multiple Providers in Persons Without Cancer (OMP).
This guest blog is one in a series by sponsors of the 2024 PQA Annual Meeting on a survey which highlights opportunities for pharmacies and payers to boost medication compliance. PQA does not endorse, recommend or favor any product, service or organization that is a sponsor.
The 2024 PQA Annual Meeting is just 10 days away! The PQA Annual Meeting consistently brings together stakeholders from across healthcare focused on improving quality medication use. Connecting with old colleagues, and making new acquaintances, is consistently a top-rated benefit of the meeting. .
The PQA Postdoctoral Executive Fellowship helps produce the next generation of leaders in health care quality through a full-time, 12-month program. Executive Fellows collaborate with PQA staff, members and other stakeholders on a variety of initiatives to improve medication use quality. During the fellowship, individuals will expand their skills and experience in project management, quality measure design and implementation, non-profit administration and association management, and health care quality research.
Collaboration is one of PQA's greatest attributes, and our measure development process embodies how our diverse member organizations reach consensus on evaluating medication use quality. The public comment period is an important part of our systematic and transparent consensus-based process.
The upcoming 2024 PQA Annual Meeting's poster session will showcase 23 quality improvement and research projects. Sponsored by Pharmacy Quality Solutions, this session offers authors a platform to exhibit their work and enables attendees to engage in insightful discussions about healthcare quality.
Have you made your plans to attend the 2024 PQA Annual Meeting? This year's meeting will be held in Baltimore from May 14 -16. Early registration ends Friday, April 19; register today to take advantage of the member discount!
The 2024 PQA Annual Meeting is less than six weeks away, and we are excited to welcome you all back to Baltimore!
PQA is a non-profit organization with 250 diverse members across healthcare. Our members include community and specialty pharmacy organizations, pharmacists and other healthcare providers, pharmacies, health plans, pharmacy benefit managers, life sciences, technology vendors, government agencies, health information technology partners, researchers, accrediting organizations and academia.
Today is an exciting and important day for PQA. The PQA Board of Directors completed the sale of all of PQA’s shares in Pharmacy Quality Solutions (PQS) to Innovaccer, a San Francisco, CA based healthcare technology company with a platform unifying patient data across systems and care settings. A statement from our Board Chair, Susan Cantrell, followed the Innovaccer’s announcement at the HIMSS Global Health Conference & Exhibition in Orlando.
Have you made your plans to join us at the 2024 PQA Annual Meeting, May 14-16, in Baltimore? There are plenty of volunteer opportunities available to attendees who want to maximize their involvement at the meeting.
February 29 was Rare Disease Day, providing an opportunity to raise awareness of the impact of rare diseases. Ensuring the quality of medication use is critically important for rare disease patients, payers, clinicians, specialty pharmacies and everyone with a role in the care process.
Today is Rare Disease Day. It’s an opportunity to raise awareness of the impact of rare diseases.
PQA is working with its members and the broader medication therapy management (MTM) community to build consensus on the research, measurement and strategies needed to evolve our national approach to evaluating MTM service quality.
As a healthcare quality educator, PQA offers a wide range of learning and education opportunities. The goal of our education programs is to promote the use and impact of PQA measures and advance the quality of medication use through research, strategic partnerships, collaboration and a variety of learning venues.
Patients, caregivers, family members and advocates have a critical role to play in high-quality medication use. They provide unique and valuable insights about what is important and meaningful in medication use quality, which supports the development of appropriate and useful quality measures, as well as related education, research and tools that support informed health care decisions and better medication use outcomes.
PQA mourns the passing of CMS Chief Medical Officer Jeffrey Kelman, MD, MMSc. Kelman served on the PQA Board of Directors for 10 years and most recently served on the board as a CMS Special Advisor. Kelman was a trusted advisor to PQA since its establishment in 2006. He was kind, generous and thoughtful in his support of PQA and its mission.
Kelman joined CMS in 2005 and helped implement the Part D program. He was a passionate advocate for patient-centered care and efforts to improve the quality of medication use. On behalf of our board, members and staff, PQA sends condolences to his family, friends, colleagues and the countless lives he touched during his life and career.
See Dr. Kelman's obituary for more on his life, accomplishments and family.
